Evidence method
Level · gp.fundamentals.debt_to_revenue
142.75% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
TCRX · Dec 31, 2023
TScan Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-24-026875General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
14.95% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-291.50% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
55.52% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-444.00% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
418.80% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
24.74% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History11 statesHistory building
Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20267/7 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 770.39%
- Current
- 142.75%
- Delta
- -627.64%
- Previous
- 36.51%
- Current
- 14.95%
- Delta
- -21.56%
- Previous
- 206.25%
- Current
- -291.50%
- Delta
- -497.75%
- Previous
- -636.69%
- Current
- -444.00%
- Delta
- 192.68%
- Previous
- 585.05%
- Current
- 418.80%
- Delta
- -166.25%
- Previous
- 34.50%
- Current
- 24.74%
- Delta
- -9.76%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · TCRX Fundamental State →Has State · TScan Therapeutics, Inc. →Transitioned To · TCRX BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · TCRX CAPEX_INTENSITY_DECREASED →Transitioned To · TCRX CASH_GENERATION_DECREASED →Transitioned To · TCRX PROFITABILITY_INCREASED →Transitioned To · TCRX R_AND_D_INTENSITY_DECREASED →Transitioned To · TCRX SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.